Bristol-Myers Squibb CompanyBMYNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.54% | -5.60% | +0.56% | +2.77% | +1.30% |
| Gross Profit Growth | +14.36% | +11.38% | +18.66% | +32.79% | +13.21% |
| EBITDA Growth | -42.73% | +0.00% | -25.35% | -3.90% | -13.99% |
| Operating Income Growth | +29.66% | +129.38% | +59.33% | +59.05% | -43.94% |
| Net Income Growth | -95.91% | +0.00% | -22.02% | +81.75% | +1408.33% |
| EPS Growth | -95.92% | +0.00% | -22.89% | +80.00% | +1392.96% |
| EPS Diluted Growth | -95.94% | +0.00% | -22.89% | +80.00% | +1401.42% |
| Weighted Average Shares Growth | +0.10% | +0.40% | +0.39% | +0.49% | +0.59% |
| Weighted Average Shares Diluted Growth | +0.20% | +0.69% | +0.44% | +0.34% | +0.20% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +4.40% | -31.05% | +68.40% | +12.88% | -55.53% |
| Free Cash Flow Growth | +3.54% | -33.57% | +72.29% | +13.75% | -60.50% |
| Receivables Growth | -5.50% | +3.74% | -0.30% | -1.87% | +0.70% |
| Inventory Growth | -3.94% | -10.69% | -11.05% | -17.23% | +5.20% |
| Asset Growth | -2.69% | -6.67% | +0.03% | +3.44% | -2.77% |
| Book Value per Share Growth | -44.55% | +5.04% | +2.07% | +7.70% | +12.43% |
| Debt Growth | +23.48% | -10.75% | -5.69% | -0.70% | -7.93% |
| R&D Expense Growth | +12.60% | -17.00% | -1.44% | +7.44% | -7.25% |
| SG&A Expenses Growth | -10.27% | -32.95% | -12.02% | -9.46% | +17.76% |